DOI 10.21037/tlcr-2025-aw-1305
Adjuvant epidermal growth factor receptor tyrosine kinase inhibitor in resected stage N2 non-small cell lung cancer harboring EGFR mutation.
Аннотация
BACKGROUND
Adjuvant therapy with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is effective and safe for patients with completely resected non-small cell lung cancer (NSCLC) with EGFR mutations, but certain issues remain unresolved. This retrospective study aimed to investigate the optimal adjuvant treatment regimen and duration of EGFR-TKI treatment, evaluate the efficacy of different generations of EGFR-TKIs, and identify prognostic factors for patients with stage N2 EGFR-mutant NSCLC.
METHODS
From July 31, 2010, to July 31, 2022, clinicopathological data were collected from 190 patients with N2 EGFR-mutant NSCLC who underwent complete surgical resections. Patients received either postoperative adjuvant EGFR-TKI monotherapy or adjuvant combination therapy with EGFR-TKI (chemotherapy, radiotherapy, or radiochemotherapy prior to EGFR-TKI therapy). Overall survival (OS) and disease-free survival (DFS) were assessed.
RESULTS
The median follow-up of the 190 patients was 49 months, with a 4-year DFS rate being 41.3% and the 4-year OS rate being 80.2%. Among these patients, 127 (66.8%) received EGFR-TKI monotherapy, while 63 (33.2%) received combination therapy. Pathological tumor-node-metastasis (pTNM) stage (stage IIIA vs. stage IIIB; P=0.01) and generation of EGFR-TKI (third vs. first; P<0.001) were significantly associated with DFS benefit, but not with OS. The number of positive mediastinal lymph nodes (<3 vs. ≥3) correlated with both DFS (P=0.02) and OS (P=0.04) benefit. EGFR mutation status (exon 19 deletion vs. exon 21 L858R point mutation) was significantly associated with DFS (P=0.03) and OS (P=0.01). However, EGFR-TKI monotherapy and combination therapy demonstrated no significant differences in terms of DFS (P=0.73) or OS (P=0.13). Longer duration of EGFR-TKI treatment (>3 vs. ≤3 years) was associated with better DFS (P<0.001) and OS (P<0.001). Moreover, pTNM stage, generation of EGFR-TKI, and duration of EGFR-TKI treatment were identified as independent prognostic factors for DFS (all P<0.05), while duration of EGFR-TKI treatment was also an independent prognostic factor for OS (P<0.001).
CONCLUSIONS
Our study found that EGFR-TKI monotherapy and combination therapy demonstrated no significant differences in terms of DFS or OS in patients with completely resected stage N2 EGFR-mutant NSCLC. Adjuvant treatment with third-generation EGFR-TKIs and prolonged treatment duration may offer enhanced survival benefits.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.